A Phase II clinical trial has produced remarkable results in the field of longevity research. Participants receiving a novel gene therapy showed measurable reversal of cellular aging markers.
The therapy targets telomere length and mitochondrial function, two key indicators of cellular age. After six months of treatment:
The trial involved 300 participants aged 55-75. The treatment group showed biological age reductions averaging 5-8 years compared to their chronological age.
"We're not just slowing aging — we're seeing genuine reversal of specific aging processes," said the principal investigator. "While we're far from a fountain of youth, this is a significant step."
A Phase III trial involving 2,000 participants is expected to begin later this year.